Moderna reinstated with an Underperform at BofA

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines company,” citing COVID revenue stream uncertainty even if RFK Jr. doesn’t become head of the HHS. The firm also has “mixed views” on the company’s current late-stage pipeline, the analyst tells investors.